Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04671056 · ClinicalTrials.gov registry record · Phase 1
Drug Interaction Study of MGL-3196 With Pioglitazone
A Phase 1 study, sponsored by Madrigal Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT04671056 is a Phase 1 study that has completed, run by Madrigal Pharmaceuticals. The registered enrollment target is 16 participants.
The verdict
NCT04671056, a Phase 1 study, has completed, sponsored by Madrigal Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
Interventions
- DRUG Pioglitazone 15mg
- DRUG MGL-3196
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-09 |
| Est. Completion | 2019-01-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04671056
The ClinicalTrials.gov registry entry for NCT04671056 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Madrigal Pharmaceuticals, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pioglitazone 15mg is the first listed.
NCT04671056 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04671056 about?
NCT04671056 is a clinical study titled "Drug Interaction Study of MGL-3196 With Pioglitazone". The purpose of this study is to determine whether the single-dose pharmacokinetics (AUC) of pioglitazone are affected by chronic dosing with MGL-3196 100 mg/day in healthy subjects.
What is the current status of trial NCT04671056?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2018-11-09. Estimated completion is 2019-01-05.
What interventions are being tested in trial NCT04671056?
The interventions under investigation include: Pioglitazone 15mg (DRUG), MGL-3196 (DRUG).
Who is sponsoring clinical trial NCT04671056?
This trial is sponsored by Madrigal Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.